CRL Charles River Laboratories International Inc.

Charles River Launches Real-Time Research Model Ordering, Introducing an Important Digital Innovation to Research Models & Services Business

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new e-commerce ordering experience, offering clients real-time access into research model availability and pricing, as well as immediate order confirmation. The introduction of real-time ordering for Charles River’s Research Models & Services business digitizes a robust, industry-leading inventory, and provides a seamless online ordering experience.

“Traditionally, clients looking to purchase research models would review a static digital catalog, and follow-up with a phone call or email to our ordering team,” said Colin Dunn, Ph.D., Corporate Senior Vice President, Global Research Models & Services, Charles River. “Our real-time digital experience reimagines this dynamic and enables clients direct access to availability, pricing, and immediate order confirmations–empowering them to make more efficient decisions.”

By reimagining an interactive digital catalog and connecting it to dynamic inventory and pricing systems, clients are now provided with real-time purchasing information based on their delivery schedule. The intuitive digital experience enables collaboration between researchers and procurement teams to search inventory by name, species, strain code or therapeutic area, and configure their request based on research model specifications matching their study requirements and schedule.

“Implementing this real-time experience in our Research Models & Services business is the latest in a series of innovations that are fundamental to our digital journey,” said Mark Mintz, Corporate Senior Vice President, Chief Information Officer at Charles River. “We built this platform with client needs in mind, using design-led thinking to create value in their research process, ultimately working to increase efficiency in the development of new therapeutics.”

As part of Charles River’s commitment to the humane care and well-being of research animal models, trained staff qualify all requests for account access, ensuring that only authorized individuals have the ability to place orders for research models. Researchers have full access to Charles River’s research model portfolio, including account-specific pricing for effortless sharing with their procurement team to streamline purchases. As more users are onboarded onto the innovative platform, the online ordering system ensures seamless collaboration for researchers, regardless of procurement platform. The real-time ordering experience is live and currently available in North America. Charles River is continuously expanding the scope and taking into account the voice of the customer, and anticipates new features being regularly introduced.

“[It is] more convenient and easier to find the research models requested from my researchers,” said Michelle, a purchasing administrator at Case Western Reserve University. “I really like the fact that all my account and shipping information is already in the system for me to choose from. I like that I can see the price of the research models we are requesting when placing an order. We also get the confirmations back very quickly.”

Charles River is showcasing the real-time research model ordering experience at the AALAS 2023 National Meeting in Salt Lake City, UT, from October 22-26. for a demonstration from subject matter experts, and to see the latest innovations from Charles River.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit .

EN
19/10/2023

Underlying

Reports on Charles River Laboratories International Inc.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 March 2025 in which we reassessed the appropriateness of the rati...

 PRESS RELEASE

Charles River Laboratories to Present at Barclays Global Healthcare Co...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, at 9:30 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation and will rem...

 PRESS RELEASE

Charles River Announces Agreement with Singapore General Hospital

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with Singapore General Hospital (SGH) to provide Current Good Manufacturing Practice (CGMP) -compliant master cell banking (MCB) and next-generation sequencing (NGS)-based services for use in cell line characterization. SGH will use cord blood to derive and manufacture allogeneic chimeric antigen receptor (CAR) T-cells which will be used to treat patients with cancer. “We are thrilled to leverage our cell line characterization services and comprehensive NGS testing app...

Charles River Laboratories International Inc: 3 directors

Three Directors at Charles River Laboratories International Inc bought/sold/sold after exercising options 11,989 shares at between 162.500USD and 165.010USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart whi...

 PRESS RELEASE

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023. The impact of foreign currency translation reduced reported revenue by 0.1%, and an acquisition contributed 0.9% to consolidated fourth-quarter revenue. A divestiture reduced reported revenue by 0.1%. Excluding the effect of these items, revenue declined 1.8% on an organic basis. On a seg...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch